Tulane Home Tulane Shield logo linking to site home page

Tulane Liver Research

To learn more about liver research, please contact us at 504-988-3047 or click here to request additional information.  

Elaine Boos, RN, Margee Rabito, RN, Anna Hero, Martin Moehlen, MD
The research team of Tulane's Department of Gastroenterology and Hepatology:
Elaine Boos, RN, Margee Rabito, RN, Anna Hero, and Dr. Martin Moehlen

In order to understand and treat liver disease, research is essential.  The research team of Tulane's Section of Gastroenterology and Hepatology contributes to and participates in cutting edge research and clinical trials for the treatment of many liver diseases.

The volunteers who participate in these clinical trials are key in the discovery of effective, new treatments.  Our research team provides individualized, compassionate care and attention to all of our volunteers. We are currently recruiting volunteers to participate in research for the following liver diseases and conditions:

Cirrhosis

  • Galectin GT-031 A seamless, adaptive, Phase 2b/3. double-blind, randomized, placebo-controlled, multi-center, international study evaluating the efficacy and safety of Belapectin (GR-MD-02) for the prevention of esophageal varices in NASH cirrhosis (PI: Dr. Fredric Regenstein) NCT04365868
  • Gilead GS-US-454-6075: A Phase 2, randomized, double-blind, double-dummy, placebo-controlled study evaluating the safety and efficacy of Semaglutide, and the fixed-dose combination of Cilofexor and Firsocostat, alone and in combination, in subjects with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH) (PI: Dr. Moehlen) NCT04971785
  • Salix RNLC3131: A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of Rifaximin soluble solid dispersion (SSD) tablets for the delay of encephalopathy decompensation in cirrhosis (PI: Dr. Fredric Regenstein) NCT05071716

NASH (Fatty Liver Disease)

  •  Lakeside Life Sciences LLS-019: Evaluation of the diagnostic performance of the M30 Apoptosense® M65 and M65 EpiDeath ELISA Assay results to stratify non-alcoholic steatohepatitis (NASH) from simple steatosis in a cohort of patients suspected of nonalcoholic Fatty Liver Disease (NAFLD) (PI: Dr. Martin Moehlen)
  • Viking VK2809-202:  A Phase 2B, randomized double-blind, placebo-controlled, multi-center study to assess the efficacy, safety and tolerability of VK 2809 administered for 52 weeks, followed by a 4-week off-drug phase in subjects with biopsy proven, non-alcoholic steatohepatitis with fibrosis. (PI: Dr. Martin Moehlen) NCT04173065
  • Madrigal MGL-3196-11: A Phase 3, multinational, double-blind, randomized, placebo-controlled study of MGL-3196 (resmetirom) in patients with non-alcoholic steatohepatitis (NASH) and fibrosis to resolve NASH and reduce progression to cirrhosis and/or hepatic decompensation (PI: Dr. Martin Moehlen)  NCT03900429
  • AstraZeneca D5671C00006: A Phase 2b/3 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Cotadutide in participants with non-cirrhotic, non-alcoholic steatohepatitis with fibrosis (PI: Dr. Martin Moehlen) NCT05364931

Primary Biliary Cholangitis (PBC)

  •  CymaBay CB8025-31731: A long-term open label study to evaluate the safety and tolerability of Seladelpar in subjects with PBC. (PI: Dr. Martin Moehlen)

Autoimmune Hepatitis

  •  Novartis CVAY736B2201 (AMBER): A two-part randomized, double-blind, placebo-controlled, multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (AMBER) (PI: Dr. Martin Moehlen) NCT03217422

Alcoholic Hepatitis

  •  Durect C928-011 A randomized, double-blind, placebo-controlled, phase 2b study to evaluate safety and efficacy of DUR-928 in subjects with alcoholic hepatitis (PI: Dr. Fredric Regenstein) NCT04563026

If you are interested in learning more about research, please contact us at 504-988-3047 or click here to request additional information.